GlassScriptPhysician profile
Faramarz Davidi
NPI 1902010937
$3,473.92
in general payments reported to CMS, 2019-2025
11 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $362 · 2021: $218 · 2022: $300 · 2023: $1,297 · 2024: $22.65 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,651.66 | 2019-2023 | Xeomin |
| Galderma Laboratories, L.P. | $909.77 | 2019-2021 | |
| Lumenis Be INC | $213.30 | 2023 | M22 |
| Allergan, INC. | $201.60 | 2019-2022 | |
| Ocular Therapeutix, INC. | $148.30 | 2023 | Dextenza |
| Amgen INC. | $120.67 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $101.67 | 2019 | |
| Alcon Vision LLC | $45.45 | 2022 | |
| Apellis Pharmaceuticals, INC. | $34.18 | 2025 | Syfovre |
| Shire North American Group INC | $24.67 | 2019 | |
| Astellas Pharma US INC | $22.65 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faramarz Davidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.